The addition of an anti–PD-1 antibody further increased the percentage of CD8+ T cells via the IFN signaling pathway, which provides a scientific rationale for combination therapy of lenvatinib with PD-1 blockade to improve cancer immunotherapy11. This evidence concerns the gene IFNA1 and cancer.